Results 11 to 20 of about 3,654 (190)

Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir–Velpatasvir and Sofosbuvir–Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis

Saudi Journal of Kidney Diseases and Transplantation, 2023
Patients with end-stage renal disease (ESRD) are at an increased risk of hepatitis C virus (HCV) infection. This study evaluated the prevalence of HCV infection in patients with ESRD on maintenance hemodialysis (MHD) and studied the effectiveness of ...
Mohammad Ashraf Bhat, Aadil Nabi Mir, Manzoor Ahmad Parry, Irshad Ahmad Parray   +3 more
doaj   +2 more sources

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 1; peer review: 2 approved] [PDF]

F1000Research, 2020
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong   +2 more
doaj   +2 more sources

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure

Drug Design, Development and Therapy, 2017
Fazia Mir, Alp S Kahveci, Jamal A Ibdah, Veysel Tahan Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA Abstract: Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide ...
Mir F, Kahveci AS, Ibdah JA, Tahan V
doaj   +1 more source

Sofosbuvir/velpatasvir: A promising combination

World Journal of Hepatology, 2016
Hepatitis C virus (HCV) affects 3% of the world population. It represents the main cause of chronic liver disease and is responsible for extra-hepatic complications, such as type 2 diabetes and cardiovascular diseases. HCV includes 7 genotypes differing in the nucleotide sequence variability, the geographic distribution, the rates of viral clearance ...
BONAVENTURA, ALDO, MONTECUCCO, FABRIZIO
openaire   +3 more sources

Safety and Drug-Drug Interaction Burden of Direct-Acting Antiviral Therapy for Hepatitis C: A Single-Center Community Hospital Analysis. [PDF]

Int J Hepatol
Background Polypharmacy leads to drug–drug interactions (DDIs) with direct‐acting antivirals (DAAs). We quantified the DDI burden (Liverpool categories) and evaluated its association with effectiveness and safety. We assessed renal function as a predictor of adverse events (AEs) and reported loss to follow‐up (LTFU). Methods We retrospectively analyzed
Okabe S, Doi A, Matsumoto K, Yamamoto M, Fukui K, Nishida T.   +5 more
europepmc   +2 more sources

Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection

, 2022
Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic HCV infection. In the USA and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indicated for adults who previously received an HCV NS5A inhibitor.
Leszek Szenborn, Bandita Parhy, Anna Mania, Deirdre Kelly, Chia-Hsiang Hsueh, Sanjay Bansal, Vania Giacomet, Raffaele Iorio, Gabriella Nebbia, Kathryn Kersey, Jiang Shao, Mun Sang Yue, Alessandra Mangia, Guiseppe Indolfi, Malgorzata Pawlowska   +14 more
core   +2 more sources

Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C

Журнал инфектологии, 2023
Aim – to evaluate the effect of direct antiviral drugs (sofosbuvir and velpatasvir) on the formation of the metabolic syndrome in patients with chronic hepatitis C with a high risk of its development 2 years after treatment.Materials and methods.
A. F. Novikova, D. A. Kokorev, D. Yu. Konstantinov, L. L. Popova   +3 more
doaj   +1 more source

Biochemical study on the response to HCV therapy (Velpatasvir containing regimen), (vosevi) among adult patients’ non-responders to treatment in Fayoum Egypt [PDF]

Delta Journal of Science, 2023
Background: oral medications for the treatment of hepatitis C virus (HCV) infection, direct-acting antiviral agents (DAAs) are recommended. Worldwide, DAAs-based regimens have achieved excellent cure rates with a respectable profile of safety and a ...
Hasnaa Kamal, Nancy Atta, Naglaa Ismael, Heba Aldash, Ahmed Gomaa   +4 more
doaj   +1 more source

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. [PDF]

, 2021
BACKGROUND AND AIMS Shortened duration therapy for acute and recent hepatitis C virus (HCV) infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens, however large randomised studies
Marks, Phillipa, Hellard, Margaret, Rockstroh, Juergen, Martinello, Marianne, Matthews, Gail V, Dore, Gregory J, Ingiliz, Patrick, Rockstroh, Jürgen, Petoumenos, Kathy, Feld, Jordan J, Thurnheer, Christine, Feld, Jordan, Bhagani, Sanjay, Bruneau, Julie, Van der Valk, Marc, Kim, Arthur, Marks, Pip, Applegate, Tanya, Rauch, Andri, Gane, Ed, Grebely, Jason, Shaw, David, Applegate, Tanya L, Dore, Greg, Matthews, Gail, Nelson, Mark   +25 more
core   +2 more sources

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3

Journal of University Medical & Dental College, 2020
BACKGROUND & OBJECTIVE: The role of Velpatasvir/Sofosbuvir in the treatment of hepatitis C virus type 3 infection is evaluated in terms of virologic responses. i.e Rapid Virological Response (RVR) End of treatment response (ETR) and Sustained virological
Muhammad Sarfraz, Arshad Rabbani
doaj   +1 more source